/ Print /

David Calabrese, RPh, MHP
Four ways PBMs must change to thrive in the future
Four ways PBMs must change to thrive in the future
The days of the traditional, channel-focused and largely enshrouded PBM business model have come and gone. Here’s what’s next.
Five ways you can help fight the opioid epidemic
The opioid crisis in the U.S. is a multidimensional problem requiring a multistakeholder solution.
Top 10 sessions to attend at the AMCP Annual Meeting 2016
This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature several sessions of important to managed care professionals. Here are our top 10 recommendations.
Brand-name patent losses raise pharma cost concerns
A number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
Six ways to combat pharma price gouging
Drug price increases can prove challenging for payers. Here’s six strategies to keep in your arsenal.
New program aims to improve compound medication safety
OptumRx program aims to ensure that optimal standards of quality are upheld by the pharmacies that produce and dispense them. Here's how the program works.
[BLOG]: Use and abuse of opioids: FDA responds
In this blog post, David Calabrese RPh, MHP and Andrea Marks, MS discuss Catamaran's research on opioid abuse. Catamaran is concerned about opioid misuse and is moving forward with plans to combat opioid abuse.
Health IT will drive closer alignment for all stakeholders
"Pharmacosynchrony” is a new concept rapidly attracting interest
“Breakthrough Therapy” Designation: FDA’s Newest Mechanism for Accelerating Approval for Promising Pipeline Therapies
In July of 2012, a provision in the newly ratified Food and Drug Administration Safety and Innovation Act, paved the way for the FDA to further assist drug manufacturers in expediting the development and introduction of new drugs demonstrating early signs of advancement in the treatment of key conditions. Known as the “breakthrough therapy” designation, this new tool is seen by many as yet another positive sign that the FDA is committed to ensuring that innovative drug products are brought to market even more quickly for the millions of patients with serious medical conditions, desperately in need of new therapeutic options.
Breakthrough therapy designation: FDA’s newest mechanism for accelerating approval for promising pipeline therapies
In July of 2012, a provision in the newly ratified Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA), paved the way for the FDA to further assist drug manufacturers in expediting the development and introduction of new drugs demonstrating early signs of advancement in the treatment of key conditions. Known as the “breakthrough therapy” designation, this new tool is seen by many as yet another positive sign that the FDA is committed to ensuring that innovative drug products are brought to market even more quickly for the millions of patients with serious medical conditions, desperately in need of new therapeutic options.